Edition:
India

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

0.22USD
12:26am IST
Change (% chg)

$-0.01 (-4.57%)
Prev Close
$0.23
Open
$0.22
Day's High
$0.23
Day's Low
$0.21
Volume
132,379
Avg. Vol
127,603
52-wk High
$1.08
52-wk Low
$0.19

Chart for

About

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize,... (more)

Overall

Beta: 3.13
Market Cap(Mil.): $38.52
Shares Outstanding(Mil.): 100.06
Dividend: --
Yield (%): --

Financials

BRIEF-Bio Path Holdings Provides Clinical Update And 2018 Business Outlook

* BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2018 BUSINESS OUTLOOK

30 Dec 2017

BRIEF-Bio-Path Holdings Q3 loss per share $0.02

* Bio-Path Holdings reports third quarter 2017 financial results

10 Nov 2017

BRIEF-Bio-Path Holdings announces $4 mln registered direct offering

* Bio-Path Holdings, Inc. Announces $4 million registered direct offering

03 Nov 2017

BRIEF-Bio Path Holdings receives notice of allowance for key U.S. composition of matter patent

* Bio Path Holdings - U.S. PTO has issued notice of allowance for claims related to co's liposomal delivery and antisense technology, dnabilize Source text for Eikon: Further company coverage:

19 Jul 2017

BRIEF-Bio-Path Holdings appoints Mark Colonnese to its board

* Bio-Path Holdings appoints Mark Colonnese to its board of directors Source text for Eikon: Further company coverage:

17 Jul 2017

Competitors

Earnings vs. Estimates